These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 25654512)

  • 1. For what illnesses is a disease management program most effective?
    Jutkowitz E; Nyman JA; Michaud TL; Abraham JM; Dowd B
    J Occup Environ Med; 2015 Feb; 57(2):117-23. PubMed ID: 25654512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The 3-year disease management effect: understanding the positive return on investment.
    Nyman JA; Jeffery MM; Abraham JM; Jutkowitz E; Dowd BE
    J Occup Environ Med; 2013 Nov; 55(11):1356-64. PubMed ID: 24164767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effectiveness of health promotion at the University of Minnesota: expenditures, absenteeism, and participation in specific programs.
    Nyman JA; Barleen NA; Abraham JM
    J Occup Environ Med; 2010 Mar; 52(3):269-80. PubMed ID: 20190655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes and lessons learned from evaluating TRICARE's disease management programs.
    Dall TM; Askarinam Wagner RC; Zhang Y; Yang W; Arday DR; Gantt CJ
    Am J Manag Care; 2010 Jun; 16(6):438-46. PubMed ID: 20560687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of care coordination on hospitalization, quality of care, and health care expenditures among Medicare beneficiaries: 15 randomized trials.
    Peikes D; Chen A; Schore J; Brown R
    JAMA; 2009 Feb; 301(6):603-18. PubMed ID: 19211468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disease management practices of health plans.
    Welch WP; Bergsten C; Cutler C; Bocchino C; Smith RI
    Am J Manag Care; 2002 Apr; 8(4):353-61. PubMed ID: 11950130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A return-on-investment analysis of the health promotion program at the University of Minnesota.
    Nyman JA; Barleen NA; Dowd BE
    J Occup Environ Med; 2009 Jan; 51(1):54-65. PubMed ID: 19136874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of an integrated disease management program in reducing exacerbations in patients with severe asthma and COPD.
    Jain VV; Allison R; Beck SJ; Jain R; Mills PK; McCurley JW; Van Gundy KP; Peterson MW
    Respir Med; 2014 Dec; 108(12):1794-800. PubMed ID: 25294691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of disease management on health care utilization: evidence from the "Florida: A Healthy State (FAHS)" Medicaid Program.
    Afifi AA; Morisky DE; Kominski GF; Kotlerman JB
    Prev Med; 2007 Jun; 44(6):547-53. PubMed ID: 17350086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving primary care for patients with chronic illness: the chronic care model, Part 2.
    Bodenheimer T; Wagner EH; Grumbach K
    JAMA; 2002 Oct; 288(15):1909-14. PubMed ID: 12377092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disease management 360 degrees: a scorecard approach to evaluating TRICARE's programs for asthma, congestive heart failure, and diabetes.
    Yang W; Dall TM; Zhang Y; Hogan PF; Arday DR; Gantt CJ
    Med Care; 2010 Aug; 48(8):683-93. PubMed ID: 20613658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health and disability costs of depressive illness in a major U.S. corporation.
    Druss BG; Rosenheck RA; Sledge WH
    Am J Psychiatry; 2000 Aug; 157(8):1274-8. PubMed ID: 10910790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of four disease management programs: evidence from blue cross blue shield of Louisiana.
    Liu M; Yuan X; Ouyang J; Chaisson J; Bergeron T; Cantrell D; Washington V; Zhang Y; Nigam S
    J Med Econ; 2020 Jun; 23(6):557-565. PubMed ID: 31990232
    [No Abstract]   [Full Text] [Related]  

  • 14. Cost of chronic disease in California: estimates at the county level.
    Brown PM; Gonzalez M; Dhaul RS
    J Public Health Manag Pract; 2015; 21(1):E10-9. PubMed ID: 25414965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disease management programs: benchmarking costs, savings, ROI.
    Healthc Benchmarks; 1998 Aug; 5(8):117-9. PubMed ID: 10181998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Examining costs of chronic conditions in a Medicaid population.
    Garis RI; Farmer KC
    Manag Care; 2002 Aug; 11(8):43-50. PubMed ID: 12232928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Indiana Chronic Disease Management Program's impact on medicaid claims: a longitudinal, statewide evaluation.
    Katz BP; Holmes AM; Stump TE; Downs SM; Zillich AJ; Ackermann RT; Inui TS
    Med Care; 2009 Feb; 47(2):154-60. PubMed ID: 19169115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of rheumatoid arthritis on medical expenditures, absenteeism, and short-term disability benefits.
    Ozminkowski RJ; Burton WN; Goetzel RZ; Maclean R; Wang S
    J Occup Environ Med; 2006 Feb; 48(2):135-48. PubMed ID: 16474262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diabetes and asthma costs, utilization calculated for entire episodes of treatment.
    Data Strateg Benchmarks; 1998 Sep; 2(9):136-9. PubMed ID: 10345384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low back pain, work absenteeism, chronic back disorders, and clinical findings in the low back as predictors of hospitalization due to low back disorders: a 28-year follow-up of industrial employees.
    Kääriä S; Kaila-Kangas L; Kirjonen J; Riihimäki H; Luukkonen R; Leino-Arjas P
    Spine (Phila Pa 1976); 2005 May; 30(10):1211-8. PubMed ID: 15897838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.